Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MGLL | Q99685 | 8/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366063 | 0.89 | MGLL (0.68) | MEN1KMT2AMGLLHSD11B1 | |
| SCHEMBL2366364 | 0.84 | MEN1 (0.58) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2366367 | 0.83 | KMT2A (0.49) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL6235216 | 0.83 | MEN1 (1.00) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2366269 | 0.80 | MEN1 (0.65) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2366277 | 0.80 | MEN1 (0.65) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL1720669 | 0.78 | MEN1 (0.88) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2366856 | 0.78 | MEN1 (0.61) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2366852 | 0.78 | MEN1 (0.61) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL2535612 | 0.77 | DGAT1 (0.51) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | MEN1 2896/4885KMT2A 800/4885MGLL 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.